Water-Dispersible Omega-3 Micelles for Faster Intestinal Absorption
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Bioactive lipophilic compounds, such as Omega-3 fatty acids, have low bioavailability due to their insolubility in aqueous media, leading to inefficient absorption by the body, especially in micelle formation processes that occur too late in digestion, resulting in low therapeutic efficacy and the need for high dosages.
Innovation Solution
A water-dispersible composition comprising Omega-3 fatty acids and micelle-promoting agents like carrier oils, solvents, emulsifiers, and antioxidants forms micelles with a mean diameter of 1 to 20 micrometers, promoting at least a twofold increase in bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If lipophilic compounds are administered in oil solution or water/oil suspension or emulsion, then the compound can be administered to patient, but bioavailability is poor with low concentration and long build-up time in systemic circulation
Solution Approach 1:
The patent applies preliminary action by pre-forming micelles containing the lipophilic compound before administration. These pre-formed micelles are designed to remain stable through digestion and directly deliver the compound to absorptive sites in the small intestine, eliminating the delay associated with natural micelle formation during digestion. This preliminary preparation ensures the compound is ready for immediate absorption upon reaching the target site.
Solution Approach 2:
The patent uses an intermediary approach by employing specially designed micellar carriers as mediators between the lipophilic compound and the aqueous digestive environment. These micelles act as intermediate structures that protect the hydrophobic compound during digestion while presenting a hydrophilic exterior for dispersion in aqueous media, facilitating efficient delivery to absorption sites.
2Reliability
If micelle formation occurs naturally in small intestine after bile secretion, then lipophilic compounds can be enveloped in micelles, but significant time delay occurs and many micelles are expelled as waste because formed too late in digestion
Solution Approach 1:
The invention applies preliminary action by pre-forming stable micelles containing the lipophilic compound before administration. These pre-formed micelles are designed to remain stable through the digestive process and directly reach absorptive sites in the small intestine, eliminating the time delay associated with natural micelle formation that occurs only after bile secretion. The micelles are prepared in advance to ensure they are ready for immediate absorption upon reaching the target site.
3Reliability
If higher dosages of lipophilic compounds are administered to ensure sufficient uptake, then therapeutic benefit can be achieved, but the requirement for large amounts increases burden and reduces efficiency
Solution Approach 1:
The patent applies parameter changes by modifying the physical and chemical parameters of the delivery system. Specifically, it changes the micelle size distribution (mean diameter 1-20 micrometers), surface properties (through surfactant selection), and stability characteristics (through composition formulation). These parameter optimizations enhance the efficiency of each micelle in delivering the lipophilic compound, allowing therapeutic benefits to be achieved with lower dosages.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition significantly enhances Omega-3 absorption by forming stable micelles that attach to intestinal mucous membranes, allowing for higher bioavailability and reduced dosage requirements.
Implementation Method 1
Through interaction with chemicals carried in bile, the lipophilic species can be 'enveloped' in a micelle. The chemicals act as surfactants and are molecules formed from a long lipophilic tail with a hydrophilic head. A typical micelle in aqueous solution forms an aggregate with the hydrophilic 'head' regions in contact with surrounding solvent, sequestering the hydrophobic single-tail regions in the micelle centre.
Implementation Method 2
A water-dispersible composition comprising at least one source of Omega-3 and micelle-promoting agents comprising one or more of carrier oils, solvents, emulsifiers and antioxidants
Data Source
AI summary
The present invention provides for a water-soluble composition comprising at least one source of Omega-3 comprising at least one Omega-3 fatty acid selected from eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), docosapentaenoic acid (DPA) and alpha-linolenic acid (ALA), and micelle-promoting agents comprising one or more of carrier oils, solvents, emulsiiiers and antioxidants, in order to promote an increase in biovailability of the Omega-3 Source of at least two times.